Evidence links cancer with microbiota has been accumulating. Microbes can cause cancer, expedite tumor growth and metastasis through regulating immune response. Different immunoproflings have been identified after microbiota shift through fecal microbiota transplantation (FMT) in preclinical models and cancer patients. However, the associations of gut microbiota, intratumoral bacteria and immunoregulatory properties should be further explored. As we better understood the systemic and tumor immunological principles, the progress has been made in cancer immunotherapy. Microbial metabolic effect has been suggested as a crucial transmitter to achieve antitumor effects and improving immune checkpoint blockades (ICBs) response. Unveiling of roles of microbiota and metabolite in tumor immunoregulatory will elucidate the host-microbiome interaction and enhance the efficacy of immunotherapy. These findings will help the FMT and bacterial cancer therapeutics translate into clinics.
In this research topic, we welcome original article, review and bioinformatic studies (with in vitro/ in vivo validation), that discuss the interactions between gut microbiota and tumor microbial burden in tumorigenesis, as well as the regulatory effects of microbiota-metabolites axis and tumor epigenetics and immunoregulation. We also welcome clinical or translational studies on the connection of FMT with cancer immunotherapy. Lab-validated bioinformatics or computational analysis that predicts immunotherapy response is welcomed as well. We aim to provide insights into the mechanisms of immunotherapy-refractory tumors, leading to improvement on the effects of immunotherapy and prognosis.
We welcome submissions in the subtopics below, but not limited to:
• Identification of the associations between tumor microbial burden and immunoregulation.
• Influence of microbiota-metabolites axis and antitumor immunity in different tumor kinds.
• Effects of single type of bacteria on cancer prevention and immunotherapy response.
• Mechanisms of FMT in improving antitumor effects of immune checkpoints blockades (ICBs).
• Strategies to investigate the connections of microbiota, immunoprofilings and cancer prognosis.
• Multi-omics studies: bridging bacteriomics, metabolomics and genomics.
Please note: We encourage those submission which contribute to a clear mechanism and mission of this topic. Manuscripts consisting of bioinformatics or computational analysis of public genomic or transcriptomic databases could also be considered. Submissions which are out of scope for this section will not be accepted as part of this Research Topic.
Evidence links cancer with microbiota has been accumulating. Microbes can cause cancer, expedite tumor growth and metastasis through regulating immune response. Different immunoproflings have been identified after microbiota shift through fecal microbiota transplantation (FMT) in preclinical models and cancer patients. However, the associations of gut microbiota, intratumoral bacteria and immunoregulatory properties should be further explored. As we better understood the systemic and tumor immunological principles, the progress has been made in cancer immunotherapy. Microbial metabolic effect has been suggested as a crucial transmitter to achieve antitumor effects and improving immune checkpoint blockades (ICBs) response. Unveiling of roles of microbiota and metabolite in tumor immunoregulatory will elucidate the host-microbiome interaction and enhance the efficacy of immunotherapy. These findings will help the FMT and bacterial cancer therapeutics translate into clinics.
In this research topic, we welcome original article, review and bioinformatic studies (with in vitro/ in vivo validation), that discuss the interactions between gut microbiota and tumor microbial burden in tumorigenesis, as well as the regulatory effects of microbiota-metabolites axis and tumor epigenetics and immunoregulation. We also welcome clinical or translational studies on the connection of FMT with cancer immunotherapy. Lab-validated bioinformatics or computational analysis that predicts immunotherapy response is welcomed as well. We aim to provide insights into the mechanisms of immunotherapy-refractory tumors, leading to improvement on the effects of immunotherapy and prognosis.
We welcome submissions in the subtopics below, but not limited to:
• Identification of the associations between tumor microbial burden and immunoregulation.
• Influence of microbiota-metabolites axis and antitumor immunity in different tumor kinds.
• Effects of single type of bacteria on cancer prevention and immunotherapy response.
• Mechanisms of FMT in improving antitumor effects of immune checkpoints blockades (ICBs).
• Strategies to investigate the connections of microbiota, immunoprofilings and cancer prognosis.
• Multi-omics studies: bridging bacteriomics, metabolomics and genomics.
Please note: We encourage those submission which contribute to a clear mechanism and mission of this topic. Manuscripts consisting of bioinformatics or computational analysis of public genomic or transcriptomic databases could also be considered. Submissions which are out of scope for this section will not be accepted as part of this Research Topic.
